IFN-CSP Inhibiting Hepatitis B Virus in HepG2.2.15 Cells Involves JAK-STAT Signal Pathway

Figure 5

Blockade of the anti-HBV effect of IFN-CSP by JAK inhibitors. Confluent HepG2.2.15 cells were pretreated for 1 h with JAK inhibitor or not and then incubated with either IFN-CSP or IFNα2b for 3 days. Hepatitis B surface antigen (HBsAg; a) and hepatitis B e antigen (HBeAg; b) in the culture supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA). HBV-DNA (c) in the culture supernatants was measured by real-time quantitative PCR. Data represent the mean ± SEM of three experiments. versus untreated controls versus untreated controls, versus no JAK inhibitor controls, versus no JAK inhibitor controls.